Search results
Showing 7021 to 7035 of 7679 results
Immunosuppressive therapy for renal transplantation in adults (TA85)
This guidance has been updated and replaced by NICE technology appraisal guidance 481.
This guidance has been withdrawn.
Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)
This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.
The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder (TA66)
This guidance has been updated and replaced NICE guideline CG38.
Guidance on the use of photodynamic therapy for age-related macular degeneration (TA68)
This guidance has been updated and replaced by NICE guideline NG82.
This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).
This guidance has been updated and replaced by NICE technology appraisal guidance 764.
This guidance has been updated and replaced by NICE technology appraisal guidance 687.
Dapagliflozin with insulin for treating type 1 diabetes (TA597)
In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.
This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].
Guidance on the use of patient-education models for diabetes (TA60)
This guidance has been replaced by NICE guideline NG17.
This guidance has been updated and replaced by NICE technology appraisal guidance 770.
Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)
This guidance has been updated and replaced by NICE guideline NG199.
The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)
This appraisal has been updated and replaced by NICE guideline CG79.
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA759)
This guidance has been updated and replaced by NICE technology appraisal guidance 835.